scholarly journals Effects of luteolin-rich chrysanthemum flower extract on purine base absorption and blood uric acid in Japanese subjects

2022 ◽  
Vol 12 (1) ◽  
pp. 12
Author(s):  
Tsuyoshi Takara ◽  
Kazuo Yamamoto ◽  
Naoko Suzuki ◽  
Shin-ichiro Yamashita ◽  
Shin-ichiro Iio ◽  
...  
Keyword(s):  
Uric Acid ◽  
Placebo Group ◽  
Serum Uric Acid ◽  
Random Number Generator ◽  
Double Blind ◽  
Japanese Men ◽  
Purine Base ◽  
Flower Extract ◽  
Before And After ◽  
Body Parameters

Background and objective: Chrysanthemum flowers are consumed as fresh condiments, herbal teas, and processed foods in Japan and Taiwan. They contain luteolin as a major polyphenol and are traditionally used for eye care. We previously demonstrated that the ingestion of Chrysanthemum flower extract (CFE) for 1 month reduced serum uric acid levels. However, the findings obtained were considered to be biased because the study was performed by a CFE manufacturer. Therefore, we herein conducted a clinical trial on CFE on a larger scale and examined its effects on purine base absorption from the intestines, which represents an effective approach for reducing serum uric acid levels. Methods: Both studies were performed as randomized, double-blind, placebo-controlled trials and CFE (100 mg) containing 1 mg of luteolin was used as the active sample. We enrolled 44 healthy Japanese men and women with 6.0 to 7.9 mg/dL serum uric acid. All subjects were randomly allocated to an active group (n=22) or placebo group (n=22) using a computerized random number generator. In the purine base absorption study, CFE was ingested with a purine base-rich diet and serum uric acid levels were measured chronologically. In the 12-week consecutive ingestion study, CFE or placebo was administered between January and April 2021. Serum uric acid levels after 12 weeks were assessed as the primary outcome, and uric acid were measured before and after 4 weeks of the intervention as secondary outcomes. Blood, urine and body parameters were examined to evaluate the safety of CFE. Results: Thirty-nine subjects completed the trial, and the per protocol set comprised 18 and 21 subjects in the active and placebo groups, respectively. In the single dosing study of CFE on subjects loaded by the purine base-rich diet, no significant changes were observed between the CFE and placebo groups. On the other hand, in the 12-week ingestion study, serum uric acid levels were significantly lower in the CFE group than in the placebo group. Laboratory tests revealed no abnormalities to suggest any side effects of CFE.Conclusions: CFE (100 mg/day) containing 1 mg of luteolin reduced serum uric acid levels. CFE may be beneficial for improving hyperurichemia. Trial Registration: UMIN-CTR: UMIN000042327Foundation: The present study was funded by Oryza Oil & Fat Chemical Co., Ltd. Keywords: Chrysanthemum, luteolin, uric acid, purine base

scholarly journals A 12-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial for Evaluation of the Efficacy and Safety of DKB114 on Reduction of Uric Acid in Serum

Nutrients ◽  
2020 ◽  
Vol 12 (12) ◽  
pp. 3794
Author(s):  
Yu Hwa Park ◽  
Do Hoon Kim ◽  
Jung Suk Lee ◽  
Hyun Il Jeong ◽  
Kye Wan Lee ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Uric Acid ◽  
Placebo Group ◽  
Serum Uric Acid ◽  
Controlled Study ◽  
Efficacy And Safety ◽  
Food Ingredient ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Significant Difference

This study sought to investigate the antihyperuricemia efficacy and safety of DKB114 (a mixture of Chrysanthemum indicum Linn flower extract and Cinnamomum cassia extract) to evaluate its potential as a dietary supplement ingredient. This clinical trial was a randomized, 12-week, double-blind, placebo-controlled study. A total of 80 subjects (40 subjects with an intake of DKB114 and 40 subjects with that of placebo) who had asymptomatic hyperuricemia (7.0–9.0 mg/dL with serum uric acid) was randomly assigned. No significant difference between the DKB114 and placebo groups was observed in the amount of uric acid in serum after six weeks of intake. However, after 12 weeks of intake, the uric acid level in serum of subjects in the DKB114 group decreased by 0.58 ± 0.86 mg/dL and was 7.37 ± 0.92 mg/dL, whereas that in the placebo group decreased by 0.02 ± 0.93 mg/dL and was 7.67 ± 0.89 mg/dL, a significant difference (p = 0.0229). In the analysis of C-reactive protein (CRP) change, after 12 weeks of administration, the DKB114 group showed an increase of 0.05 ± 0.27 mg/dL (p = 0.3187), while the placebo group showed an increase of 0.10 ± 0.21 mg/dL (p = 0.0324), a statistically significant difference (p = 0.0443). In the analysis of amount of change in apoprotein B, after 12 weeks of administration, the DKB114 group decreased by 4.75 ± 16.69 mg/dL (p = 0.1175), and the placebo group increased by 3.13 ± 12.64 mg/dL (p = 0.2187), a statistically significant difference between the administration groups (p = 0.0189). In the clinical pathology test, vital signs and weight measurement, and electrocardiogram test conducted for safety evaluation, no clinically significant difference was found between the ingestion groups, confirming the safety of DKB114. Therefore, it may have potential as a treatment for hyperuricemia and gout. We suggest that DKB114 as a beneficial and safe food ingredient for individuals with high serum uric acid. Trial registration (CRIS.NIH. go. Kr): KCT0002840.

Impact of serum uric acid on incident hypertension in a worksite population of Japanese men

2018 ◽  
Vol 36 (7) ◽  
pp. 1499-1505 ◽  
Author(s):  
Yasuo Kansui ◽  
Kiyoshi Matsumura ◽  
Yuki Morinaga ◽  
Minako Inoue ◽  
Kanako Kiyohara ◽  
...  
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Japanese Men ◽  
Incident Hypertension

The Automated Determination of Serum Uric Acid

1966 ◽  
Vol 12 (11) ◽  
pp. 748-766 ◽  
Author(s):  
Stanley Morgenstern ◽  
Richard V Flor ◽  
James H Kaufman ◽  
Bernard Klein
Keyword(s):  
Uric Acid ◽  
Serum Uric Acid ◽  
Enzymatic Reaction ◽  
Enzymatic Determination ◽  
Before And After ◽  
The Difference ◽  
Automated Determination ◽  
Colorimetric Reaction ◽  
Good Agreement

Abstract An automated procedure is presented for the enzymatic determination of serum uric acid on both the AutoAnalyzer and the Robot Chemist. The procedure measures as the neocuproine complex, the difference in the amount of Cu+ formed by reaction of a Cu++-alkanolamine buffered solution with serum uric acid under precisely controlled conditions before and after uricase treatment of the serum. The difference is proportional to the true serum uric acid content. The elements contributing to the enzymatic reaction, the colorimetric reaction, and the elimination of interferences were investigated. Comparison of serum uric acid values obtained by this method with those obtained by ultraviolet spectrophotometry show very good agreement.

scholarly journals Prognostic Value of Serum Uric Acid in Patients on the Waiting List before and after Renal Transplantation

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Henrique Cotchi Simbo Muela ◽  
Jose Jayme Galvão De Lima ◽  
Luis Henrique W. Gowdak ◽  
Flávio J. de Paula ◽  
Luiz Aparecido Bortolotto
Keyword(s):  
Uric Acid ◽  
Renal Transplantation ◽  
Serum Uric Acid ◽  
Prognostic Value ◽  
Independent Risk Factor ◽  
High Serum ◽  
Increased Risk ◽  
Before And After ◽  
The Impact ◽  
The Relationship

Background.High serum uric acid (UA) is associated with increased cardiovascular (CV) risk in the general population. The impact of UA on CV events and mortality in CKD is unclear.Objective.To assess the relationship between UA and prognosis in hemodialysis (HD) patients before and after renal transplantation (TX).Methods.1020 HD patients assessed for CV risk and followed from the time of inception until CV event, death, or TX (HD) or date of TX, CV event, death, or return to dialysis (TX).Results.821 patients remained on HD while 199 underwent TX. High UA (≥428 mmol/L) was not associated with either composite CV events or mortality in HD patients. In TX patients high UA predicted an increased risk of events (P=0.03, HR 1.6, and 95% CI 1.03–2.54) but not with death. In the Cox proportional model UA was no longer significantly associated with CV events. Instead, a reduced GFR (<50 mL/min) emerged as the independent risk factor for events (P=0.02, HR 1.79, and % CI 1.07–3.21).Conclusion.In recipients of TX an increased posttransplant UA is related to higher probability of major CV events but this association probably caused concurrent reduction in GFR.

Vitamin E in the neuroprotection of cisplatin induced peripheral neurotoxicity and ototoxicity

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 9114-9114 ◽  
Author(s):  
A. Pace ◽  
S. Carpano ◽  
E. Galiè ◽  
A. Savarese ◽  
M. Della Giulia ◽  
...  
Keyword(s):  
Placebo Group ◽  
Vitamin E ◽  
Peripheral Neurotoxicity ◽  
Double Blind ◽  
Multicentric Study ◽  
Phase Ii Studies ◽  
Significant Difference ◽  
Before And After ◽  
Vitamin E Supplementation

9114 Background: Peripheral neurotoxicity is a well recognized effect of cisplatin chemotherapy that can result in severe disability and represents a major dose-limiting factor. Several phase II studies have recently investigated the role of vitamin E as neuroprotectant in the prevention of cisplatin induced peripheral neurotoxicity and ototoxicity. Methods: An Italian randomized, placebo controlled, double blind multicentric study is ongoing to confirm the role of vitamin E supplementation in the prevention of neurotoxicity and ototoxicity induced by cisplatin Patients candidates to cisplatin chemotherapy were randomised to either vitamin E supplementation (a-tocopherol 400 mg/day) or to placebo. Patients were evaluated with neurological and neurophysiological examination before and after treatment. Neurotoxicity was measured using the comprehensive clinical and neurophysiological Total Neuropathy Score (TNS). Ototoxicity was evaluated with audiometric test and acoustic evoked potential before and after treatment. Results: 81 patients have been enrolled in 3 italian oncologic centers. An interim analysis on the first 50 patients was carried out. 25 patients (11 in the vit E group and 14 in the placebo group) received a cumulative dose higher than 300 mg/mq and were evaluable for neurotoxicity. Statistical analysis showed a significant difference (p < 0.05) in median neurotoxicity score observed in vit E group (TNS=1) respect to the placebo group (TNS=5). Conclusions: This is the first randomised, placebo controlled, double blind trial exploring the efficacy of vitamin E in the neuroprotection of cisplatin neurotoxicity. The results of this study confirm the neuroprotective effect of vitamin E supplementation against cisplatin-induced neurotoxicity. No significant financial relationships to disclose.

scholarly journals Circulating levels of incretin hormones and amylin in the fasting state and after oral glucose in GH-deficient patients before and after GH replacement: a placebo-controlled study

2000 ◽  
pp. 593-599 ◽  
Author(s):  
JO Jorgensen ◽  
AM Rosenfalck ◽  
S Fisker ◽  
B Nyholm ◽  
MS Fineman ◽  
...  
Keyword(s):  
Placebo Group ◽  
Pancreatic Beta Cells ◽  
Plasma Concentrations ◽  
Controlled Study ◽  
Oral Glucose ◽  
Fasting State ◽  
Gh Treatment ◽  
Double Blind ◽  
Gh Replacement ◽  
Before And After

OBJECTIVE: Hyperinsulinemia in association with GH excess is considered a compensatory response to insulin resistance, but the possibility of alternative insulinotropic mechanisms has not been investigated in vivo. It is also unknown how GH influences the secretion from pancreatic beta-cells of amylin, a peptide which regulates prandial glucose homeostasis and may be linked to development of beta-cell dysfunction. We therefore measured plasma concentrations of two gut insulinotropic hormones, glucagon-like peptide 1 (GLP-1) and glucose-dependent insulin-releasing peptide (GIP), and total as well as non-glycosylated amylin, in 24 GH-deficient adults before and after 4 months of GH replacement (daily evening injections of 2 IU GH/m). DESIGN: Double-blind, placebo-controlled, parallel study. METHODS: All participants underwent an oral glucose tolerance test (OGTT) at 0 and 4 months. RESULTS: A 33% suppression of fasting GLP-1 concentrations was measured in the GH group at 4 months (P=0.02), whereas a non-significant increase occurred in the placebo group (P=0.08). Fasting levels of GIP and amylin did not change significantly after 4 months in either group. The incremental response in GLP-1 during the OGTT was significantly lower after GH treatment as compared with both baseline (P=0.02) and the response in the placebo group (P=0. 03). The stimulation of GIP secretion following OGTT was similar on all occasions. The OGTT-induced incremental response in non-glycosylated amylin was moderately elevated after GH treatment as compared with placebo (P=0.05). Plasma concentrations of glucose and insulin, both in the fasting state and after the OGTT, were higher after GH treatment, but the ratio between amylin and insulin remained unchanged. CONCLUSIONS: GH-induced hyperinsulinemia is accompanied by proportionate elevations in amylin concentrations and a blunting of gut GLP-1 secretion. The mechanisms underlying the suppression of GLP-1 remain to be elucidated.

Sign in / Sign up

Export Citation Format

Share Document